Litcius/Paper detail

Baricitinib reduces 30‐day mortality in older adults with moderate‐to‐severe <scp>COVID</scp> ‐19 pneumonia

Pedro Abizanda, J.M. Calbo Mayo, Marta Mas Romero, Elisa Belén Cortés Zamora, María Teresa Tabernero Sahuquillo, Luis Romero Rizos, Pedro Manuel Sánchez‐Jurado, Ginés Sánchez Nievas, Carlos Campayo Escolano, Alba Ochoa Serrano, Victoria Sánchez‐Flor Alfaro, Rita López Bru, Cristina Gómez Ballesteros, David Caldevilla Bernardo, Francisco Javier Callejas González, Fernando Andrés‐Pretel, Volker M. Lauschke, Justin Stebbing

2021Journal of the American Geriatrics Society29 citationsDOIOpen Access PDF

Abstract

BACKGROUND: Older adults are at the highest risk of severe disease and death due to COVID-19. Randomized data have shown that baricitinib improves outcomes in these patients, but focused stratified analyses of geriatric cohorts are lacking. Our objective was to analyze the efficacy of baricitinib in older adults with COVID-19 moderate-to-severe pneumonia. METHODS: This is a propensity score [PS]-matched retrospective cohort study. Patients from the COVID-AGE and Alba-Score cohorts, hospitalized for moderate-to-severe COVID-19 pneumonia, were categorized in two age brackets of age <70 years old (86 with baricitinib and 86 PS-matched controls) or ≥70 years old (78 on baricitinib and 78 PS-matched controls). Thirty-day mortality rates were analyzed with Kaplan-Meier and Cox proportional hazard models. RESULTS: Mean age was 79.1 for those ≥70 years and 58.9 for those <70. Exactly 29.6% were female. Treatment with baricitinib resulted in a significant reduction in death from any cause by 48% in patients aged 70 or older, an 18.5% reduction in 30-day absolute mortality risk (n/N: 16/78 [20.5%] baricitinib, 30/78 [38.5%] in PS-matched controls, p < 0.001) and a lower 30-day adjusted fatality rate (HR 0.21; 95% CI 0.09-0.47; p < 0.001). Beneficial effects on mortality were also observed in the age group <70 (8.1% reduction in 30-day absolute mortality risk; HR 0.14; 95% CI 0.03-0.64; p = 0.011). CONCLUSIONS: Baricitinib is associated with an absolute mortality risk reduction of 18.5% in adults older than 70 years hospitalized with COVID-19 pneumonia.

Topics & Concepts

MedicineInternal medicineHazard ratioPneumoniaCase fatality rateCoronavirus disease 2019 (COVID-19)Propensity score matchingRetrospective cohort studyProportional hazards modelCohortConfidence intervalDiseaseEpidemiologyInfectious disease (medical specialty)COVID-19 Clinical Research StudiesLong-Term Effects of COVID-19Pharmacological Receptor Mechanisms and Effects